Previous 10 | Next 10 |
home / stock / vph:cc / vph:cc news
--News Direct-- Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has obtained public reimbursement from the Quebec Government for its product Onstryv (safinamide). Saviuk told Proactive Health Canada approved Onstryv as an add-on therapy for the ...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC Canada NewsWire Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson's patients in Quebec MONTREAL , Feb. 7, 2023 /CNW Telbec/ - V...
--News Direct-- Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has released its financial results for the fourth quarter and year-ended October 31, 2022. Saviuk told Proactive the company saw record quarterly revenue of $12.7 million in 4Q 2022...
--News Direct-- Valeo Pharma chief executive Steve Saviuk joined Steve Darling from Proactive to share news the company has been told by Health Canada they have accepted for review Veru’s New Drug Submission (NDS-CV) for sabizabulin for COVID-19. Saviuk told Proactive Sabizabulin i...
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS Canada NewsWire In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduct...
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , Jan. 25, 2023 /CNW Telbec/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmace...
VALEO PHARMA ANNOUNCES SENIOR MANAGEMENT CHANGE Canada NewsWire Valeo's President and Chief Operating Officer steps down and will continue as special advisor and member of the Board of Directors MONTREAL , Nov. 21, 2022 /CNW Telbec/ - Vale...
VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE Canada NewsWire Q4-2022 revenue guidance raised to a record $12.5M - $13.0M Fiscal 2022 revenue guidance increased to a record $27.5M - $28.0M MONTREAL , Nov. 15, 2...
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) Canada NewsWire In a Phase 3 cinical study interim analysis, sabizabulin...
VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , Sept. 9, 2022 /CNW Telbec/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
--News Direct-- Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million ...
VALEO PHARMA REPORTS RECORD SECOND QUARTER 2024 REVENUES Canada NewsWire Record Q2-24 revenues of $14.1 million , up 4% over Q2-23 outpacing revenue softness in several non-core brands Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million fo...